Select Page
Event info
Date:28 Feb
Time:10:00 to 15:00
Venue:

Boost Seminar – De-risking Drug Development

This seminar will address several of today’s key challenges in drug development leading up to clinical proof of concept.
The agenda brings together a panel of speakers from academia, pharmaceutical companies and solution providers to discuss key issues from formulation design right through to effective clinical trial planning.
The final session w ill discuss how to create the optimum development package for drug licensing; a crucial consideration for many companies, and w ill include both large and small company perspectives on the best w ays to achieve this.
Date & Time: 28 February 2012, 9.30 – 15.30
Venue: Arne Jacobsens Allé 15-17, 2300 Copenhagen S, Denmark
Room: Auditorium
Price: Participations is free how ever registration is required.
Who Should Attend?
The seminar is intended for anyone w orking in the early development arena from formulation development through to clinical proof of concept. It will be an excellent opportunity to meet, exchange ideas and netw ork w ith other industry colleagues.
The event is free but attendees w ill be required to register by follow ing the link on the right. Be informed that the number of places is limited!
Agenda

9.30 Welcome Coffee & Participant Registration from
10.00 Recent advances in the oral delivery of biomolecules by Associate Professor Hanne Mørck Nielsen, University of Copenhagen
10.40 Candidate selection and formulation screening by Dr. Brian Henry, Pfizer
11.20 In-vitro methods to predict the in vivo performance of enabling formulations by Associate Professor Anette Mullertz, University of Copenhagen
Lunch Buffet
13.00 Generating meaningful clinical data early; effective clinical trial design by Professor Henning Blume, Socratec
13.40 Simple manufacturing solutions for small and large scale clinical studies by Dr. Sven Stegemann, Capsugel
14.20 Licensing your drug; What is the right development package? Industry Perspectives from Pharma and Biotech
15.00 Concluding Remarks